Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
219 Results for "
low-density
" in MedChemExpress (MCE) Product Catalog:
Products (219)
219 Results for "low-density" in MCE Product Catalog:
Cat. No.: HY-P99822
CAS No.: 2361290-85-7
Synonyms: SHR-1209
Target:
Research Areas:
Target:
Research Areas:
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED50 values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .
Cat. No.: HY-P10502A
Target:
Research Areas:
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM .
Cat. No.: HY-W423578
CAS No.: 6656-19-5
Target:
Research Areas:
LDLR regulator-1 (Compound 7b) is a regulator of the low-density lipoprotein receptor (LDLR), capable of increasing the mRNA expression of LDLR .
Cat. No.: HY-B0144AS1
Synonyms: NK-104-d5 sodium
Cat. No.: HY-129458
CAS No.: 145599-86-6
Target:
Research Areas:
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
Cat. No.: HY-148626
Target:
Research Areas:
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
Target:
Research Areas:
LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation .
Cat. No.: HY-N10638
CAS No.: 916888-49-8
Target:
Research Areas:
N-Acetyldopamine dimer-2 (compound 2) is a N-acetyldopamine dimer that can be isolated from the yellow powder form Periostracum Cicadae with antioxidant and anti-inflammatory activities. N-Acetyldopamine dimer-2 inhibits oxidized low-density lipoprotein (LDL) oxidation, ROS generation, NO production, and NF-κB activity .
Target:
Research Areas:
Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .
Cat. No.: HY-106256
CAS No.: 214140-47-3
Target:
Research Areas:
HMR-3339 is a new selective estrogen receptor modulator. HMR-3339 reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine. HMR-3339 corrects bone alterations induced by ovariectomy .
Cat. No.: HY-108744
CAS No.: 956116-90-8
Target:
Research Areas:
Pitavastatin magnesium is an orally active HMG-CoA Reductase inhibitor. Pitavastatin magnesium lowers total cholesterol and low-density lipoprotein cholesterol in a hyperlipidemic rat model. Pitavastatin magnesium can be used in research on cardiovascular and cerebrovascular diseases such as hyperlipidemia .
Cat. No.: HY-105316
CAS No.: 263262-73-3
Target:
Research Areas:
CP-800569 is an orally active cholesteryl ester transfer protein (CETP) inhibitor. CP-800569 can decrease low-density lipoprotein and postprandial triglyceride and increase high-density lipoprotein. CP-800569 can be used for the research of metabolic disease .
Cat. No.: HY-128334
CAS No.: 2365416-53-9
Target:
Research Areas:
PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .
Cat. No.: HY-19251
CAS No.: 107376-72-7
Target:
Research Areas:
CL-283796 is a potent and orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. CL-283796 reduces low-density lipoprotein (LDL) cholesterol without affecting cholesterol absorption in African green monkeys. CL-283796 can be used for hypercholesterolemia research .
Cat. No.: HY-W040221
CAS No.: 85405-03-4
Research Areas:
Butanoyl PAF, a compound closely related to Azelaoyl PC (HY-134154), maintains over 10% of the agonist potency of platelet-activating factor (PAF). Butanoyl PAF's concentration in oxidized low-density lipoprotein surpasses that of enzymatically generated PAF by more than 100-fold .
Cat. No.: HY-165512
CAS No.: 150443-71-3
Target:
Research Areas:
Nicanartine, an orally active antioxidant and lipid-lowering compound, is an antiatherogenic drug. Nicanartine inhibits the oxidation of low-density lipoprotein (LDL).
Cat. No.: HY-106278A
CAS No.: 343322-50-9
Target:
Research Areas:
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
Cat. No.: HY-123260
CAS No.: 144754-35-8
Target:
Research Areas:
S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
